Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 May 1;52(5):217-221.
doi: 10.1152/physiolgenomics.00033.2020. Epub 2020 Apr 10.

Harnessing innate immunity to eliminate SARS-CoV-2 and ameliorate COVID-19 disease

Rachel M Golonka  1 , Piu Saha  1 , Beng San Yeoh  1 , Saurabh Chattopadhyay  2 , Andrew T Gewirtz  3 , Bina Joe  1 , Matam Vijay-Kumar  1   2
Affiliations
Editorial

Harnessing innate immunity to eliminate SARS-CoV-2 and ameliorate COVID-19 disease

Rachel M Golonka et al. Physiol Genomics. .
No abstract available

Keywords: deoxyribonuclease I; flagellin; interferon; neutrophil extracellular traps; toll-like receptor 5.

PubMed Disclaimer

Conflict of interest statement

No conflicts of interest, financial or otherwise, are declared by the authors.

Figures

Fig. 1.
Fig. 1.
Innate immunity may be the key to defeat severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). In the early stage of infection, coronaviruses are capable of inhibiting host type I interferon (IFN) antiviral immune defenses. We propose to counteract this by utilizing flagellin to activate Toll-like receptor 5 (TLR5). TLR5 can induce the production of cytokines (i.e., IL-22, IL-18) and IFN-β, which may restore the impaired immune responses. In the late stage of infection, there is a proinflammatory cytokine storm initiated by innate immune cells like neutrophils (NEU). Theoretically, this can result in inappropriate levels of neutrophil extracellular traps (NETs) and reactive oxygen species (ROS) that cause unwarranted collateral damage. Deoxyribonuclease I (DNase I)-mediated degradation of NETs could provide a therapeutic avenue to suppress excess injury.
See this image and copyright information in PMC

References

    1. Ahmed SF, Quadeer AA, McKay MR. Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies. Viruses 12: 254, 2020. doi:10.3390/v12030254. - DOI - PMC - PubMed
    1. Anas AA, van Lieshout MH, Claushuis TA, de Vos AF, Florquin S, de Boer OJ, Hou B, Van’t Veer C, van der Poll T. Lung epithelial MyD88 drives early pulmonary clearance of Pseudomonas aeruginosa by a flagellin dependent mechanism. Am J Physiol Lung Cell Mol Physiol 311: L219–L228, 2016. doi:10.1152/ajplung.00078.2016. - DOI - PubMed
    1. Baron SA, Devaux C, Colson P, Raoult D, Rolain JM. Teicoplanin: an alternative drug for the treatment of COVID-19? Int J Antimicrob Agents: 105944, 2020. doi:10.1016/j.ijantimicag.2020.105944. - DOI - PMC - PubMed
    1. Baruah V, Bose S. Immunoinformatics-aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019-nCoV. J Med Virol 92: 495–500, 2020. doi:10.1002/jmv.25698. - DOI - PMC - PubMed
    1. Batlle D, Wysocki J, Satchell K. Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy? Clin Sci (Lond) 134: 543–545, 2020. doi:10.1042/CS20200163. - DOI - PubMed

Publication types

MeSH terms